1.
Belgian population norms for the EQ-5D-5L, 2018
2.
3.
4.
5.
6.
7.
8.
9.
Authors' reply to comment on "Cost-effectiveness analysis of Herpes Zoster vaccination in 50-to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, th...
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine,...
Quality-of-life: a many-splendored thing? Belgian population norms and 34 potential determinants explored by beta regression
Cost-effectiveness analysis of herpes zoster vaccination in 50-to 85-year-old immunocompetent Belgian cohorts : a comparison between no vaccination, the adjuvanted subunit vaccine,...
Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium
Childhood varicella-zoster virus vaccination in Belgium: Cost-effective only in the long run or without exogenous boosting?
Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014.
Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014
Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium